Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer
Ruth Gershoni‐Baruch(Technion – Israel Institute of Technology), Eitan Friedman(University of Pennsylvania), Georgeta Fried(Roche (Switzerland)), E. Dagan(Technion – Israel Institute of Technology), G Zelicksson(Rambam Health Care Campus), Revital Bruchim Bar-Sade(Sheba Medical Center), R Sverdlov-Shiri(Sheba Medical Center)
Cited by 20
Related Papers
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer
|JAMA|2015|513
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444